ÂÜÀòÂÒÂ×

Philip Davy has a diverse work experience history. Philip is currently the CEO of Braizon Therapeutics, Inc. since October 2022. Prior to this role, they served as the Global Head of Business Development from May 2021 to October 2022. Additionally, they worked as the Director of Business Development from January 2019 to June 2021, and as a Senior Scientist from April 2018 to June 2021 at the same company. Philip also held the position of Senior Manager of Business Development from August 2018 to January 2019 at Braizon Therapeutics, Inc.

In 2021, Philip Davy also held the role of President & CEO at Braizon Therapeutics US, Inc.

Before joining Braizon Therapeutics, Inc., Philip Davy worked as a Junior Researcher (Affiliate) and later as a Junior Researcher at the University of Hawaii at Manoa from September 2016 to present (current end date not provided). In these roles, they conducted cell and molecular biology studies for age-related disease models and managed a mouse colony with knockout strains.

Philip also served as a Graduate Assistant at the University of Hawaii at Manoa from August 2006 to June 2011, where they supervised graduate students and interns, and carried out various molecular biology experiments.

Philip Davy started their career as an Experimental Officer I at Covance from March 2006 to July 2006. Prior to that, they worked as a Server at The Monkey House from October 2004 to July 2005. Philip also served as a Security Officer at the University of St Andrews Students' Association from September 2002 to December 2003.

Philip Davy obtained a Bachelor of Science (B.Sc.) degree in Biochemistry from the University of St Andrews in the years 2000-2004. Philip then pursued a Master of Science (M.Sc.) degree in Environmental Microbiology at the University of Aberdeen from 2004 to 2005. Driven by their passion for research, Philip went on to earn a Doctor of Philosophy (Ph.D.) degree in Molecular Biosciences and Bioengineering from the University of Hawaii at Manoa between 2006 and 2011.